Business Description
Lincoln Pharmaceuticals Ltd
ISIN : INE405C01035
Total Employee Number:
1,853Compare
Compare
Traded in other countries / regions
531633.India IPO Date
2015-12-17Description
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 54.72 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | 82.12 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.3 | |||||
Beneish M-Score | -2.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.9 | |||||
3-Year EBITDA Growth Rate | 5.6 | |||||
3-Year EPS without NRI Growth Rate | 8.2 | |||||
3-Year FCF Growth Rate | 47.6 | |||||
3-Year Book Growth Rate | 14.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.75 | |||||
9-Day RSI | 40.87 | |||||
14-Day RSI | 42.93 | |||||
3-1 Month Momentum % | 10.56 | |||||
6-1 Month Momentum % | 31.9 | |||||
12-1 Month Momentum % | 16.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.25 | |||||
Quick Ratio | 4.53 | |||||
Cash Ratio | 2.18 | |||||
Days Inventory | 93.69 | |||||
Days Sales Outstanding | 90.23 | |||||
Days Payable | 100.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.3 | |||||
Dividend Payout Ratio | 0.04 | |||||
3-Year Dividend Growth Rate | 6.3 | |||||
Forward Dividend Yield % | 0.3 | |||||
5-Year Yield-on-Cost % | 0.29 | |||||
Shareholder Yield % | 0.23 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.63 | |||||
Operating Margin % | 12.4 | |||||
Net Margin % | 13.1 | |||||
EBITDA Margin % | 19.54 | |||||
FCF Margin % | 11.97 | |||||
OCF Margin % | 15.85 | |||||
ROE % | 12.29 | |||||
ROA % | 10.37 | |||||
ROIC % | 11.89 | |||||
3-Year ROIIC % | 3.08 | |||||
ROC (Joel Greenblatt) % | 33.92 | |||||
ROCE % | 15.84 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 13.79 | |||||
Forward PE Ratio | 8.48 | |||||
PE Ratio without NRI | 13.79 | |||||
Shiller PE Ratio | 15.91 | |||||
Price-to-Owner-Earnings | 12.24 | |||||
PEG Ratio | 1.92 | |||||
PS Ratio | 1.81 | |||||
PB Ratio | 1.6 | |||||
Price-to-Tangible-Book | 1.6 | |||||
Price-to-Free-Cash-Flow | 15.1 | |||||
Price-to-Operating-Cash-Flow | 11.4 | |||||
EV-to-EBIT | 8.36 | |||||
EV-to-EBITDA | 7.43 | |||||
EV-to-Revenue | 1.45 | |||||
EV-to-FCF | 12.14 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 0.94 | |||||
Price-to-Median-PS-Value | 1.4 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.78 | |||||
Price-to-Graham-Number | 0.99 | |||||
| Price-to-Net-Current-Asset-Value | 2.69 | |||||
| Price-to-Net-Cash | 11.1 | |||||
Earnings Yield (Greenblatt) % | 11.96 | |||||
FCF Yield % | 6.62 | |||||
Forward Rate of Return (Yacktman) % | 11.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lincoln Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 6,710.299 | ||
| EPS (TTM) (₹) | 43.89 | ||
| Beta | 0.8532 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 0.7 | ||
| Volatility % | 45.1 | ||
| 14-Day RSI | 42.93 | ||
| 14-Day ATR (₹) | 18.701222 | ||
| 20-Day SMA (₹) | 616.9725 | ||
| 12-1 Month Momentum % | 16.1 | ||
| 52-Week Range (₹) | 440 - 770 | ||
| Shares Outstanding (Mil) | 20.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lincoln Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lincoln Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 1.800000 Cash Dividend | 2025-09-12 | 558.70 (+0.10%) | ||
| INR 1.800000 Cash Dividend | 2024-09-13 | 771.70 (-1.69%) | ||
| 0.2:1 Stock Split | 2009-03-19 | -- |
Show
Entries
Lincoln Pharmaceuticals Ltd Frequently Asked Questions
What is Lincoln Pharmaceuticals Ltd(NSE:LINCOLN)'s stock price today?
The current price of NSE:LINCOLN is ₹606.95. The 52 week high of NSE:LINCOLN is ₹770.00 and 52 week low is ₹440.00.
When is next earnings date of Lincoln Pharmaceuticals Ltd(NSE:LINCOLN)?
The next earnings date of Lincoln Pharmaceuticals Ltd(NSE:LINCOLN) is .
Does Lincoln Pharmaceuticals Ltd(NSE:LINCOLN) pay dividends? If so, how much?
The Dividend Yield %  of Lincoln Pharmaceuticals Ltd(NSE:LINCOLN) is 0.3% (As of Today), Highest Dividend Payout Ratio of Lincoln Pharmaceuticals Ltd(NSE:LINCOLN) was 0.12. The lowest was 0.04. And the median was 0.05. The  Forward Dividend Yield % of Lincoln Pharmaceuticals Ltd(NSE:LINCOLN) is 0.3%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Lincoln Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers